title: Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.
abstract: Sclerosing bone dysplasias are a group of rare, monogenic disorders characterized by increased bone density resulting from the disturbance in the fragile equilibrium between bone formation and resorption. Over the last decade, major contributions have been made toward better understanding of the pathogenesis of these conditions. These studies provided us with important insights into the bone biology and yielded the identification of numerous drug targets for the prevention and treatment of osteoporosis. Here, we review this heterogeneous group of disorders focusing on their utility in the development of novel osteoporosis therapies.
authors.affiliation: Department of Medical Genetics, University and University Hospital of Antwerp, Edegem, Belgium.
authors.forename: Igor
authors.initials: I
authors.lastname: Fijalkowski
authors.forename: Eveline
authors.initials: E
authors.lastname: Boudin
authors.forename: Geert
authors.initials: G
authors.lastname: Mortier
authors.forename: Wim
authors.initials: W
authors.lastname: Van Hul
mesh_terms: D015519:Bone Density / Q000235:genetics; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001862:Bone Resorption / Q000235:genetics / Q000378:metabolism; D055808:Drug Discovery; D006801:Humans; D058990:Molecular Targeted Therapy; D010009:Osteochondrodysplasias / Q000235:genetics* / Q000378:metabolism; D010012:Osteogenesis / Q000235:genetics; D010024:Osteoporosis / Q000188:drug therapy*; D010026:Osteosclerosis / Q000235:genetics* / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents